“Is curing patients a sustainable business model?”

No financial incentive in creating definite cures


Tue, Apr 17th, 2018 11:00 by capnasty NEWS

According to CNBC, a report by a Goldman Sachs analysts notes that gene therapy treatment could be "bad for business in the long run."

"The potential to deliver 'one shot cures' is one of the most attractive aspects of gene therapy, genetically-engineered cell therapy and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies," analyst Salveen Richter wrote in the note to clients Tuesday. "While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow."



You may also be interested in:

"It’s not apocalyptic until it is."
"Correct a single error out of the three billion 'letters' of our genetic code."
Cure for Ebola Outbreak Appears to Have Been Found
Sandy is a Taste of Things to Come: Survival Gear for the Next Storm
The Psychological Impact on the Daily Exposure to Bad News Reported by the Media